European approval of HIV drug darunavir will provide a potent new option with Fuzeon

Basel (CH), 16 February 2007. Today's conditional marketing authorisation in the European Union of the new protease inhibitor (PI) darunavir (boosted with ritonivir) provides physicians with the opportunity to build a potent new treatment combination with the fusion inhibitor, FUZEON. The combination of FUZEON and boosted darunavir has been shown to give treatment-experienced patients a better chance of achieving an undetectable viral load than boosted darunavir without FUZEON. This crucial goal of therapy is associated with a better outlook1 but has for a long time been considered an unrealistic goal for patients with resistance to many HIV medications.

"It is clear that in 2007 we are entering a new era where an undetectable viral load is the primary objective for all treatment-experienced patients," said Dr Anton Pozniak, consultant physician from the Chelsea and Westminster Hospital, London. "The availability of new active therapies such a darunavir/r, in combination with FUZEON, gives patients a better chance of achieving this goal."

The growing body of evidence from studies such as TORO 1 and 2, RESIST 1 and 2, POWER 1 and 22 has prompted influential international guidelines to recommend combining drugs with a new mechanism of action such as FUZEON, with an active boosted PI, such as darunavir/r, as one of the best approaches to achieving an undetectable viral load in treatment-experienced patients. 3, 4, 5, 6 The consequences of maintaining a patient on a failing regime includes the emergence of drug resistance and the swift loss of much needed active treatments.

Dr Malte Schutz, International Medical Leader at Roche, further commented: "We welcome the European approval of Tibotec's drug, darunavir/r, and understand that this is an important development for patients faced with multiple drug resistance who are most in need of new treatment options."


Contact: Peter Impey

Page: 1

Related biology news :

1. European Science Foundations Forward Look reaches out beyond the endless frontiers
2. The UAB heads a European research project on proteases and pathological processes
3. Journalists can register now for ECCO 14 -- the European Cancer Conference
4. Climate changes brews trouble for marine life in European Seas, Marine Board-ESF report says
5. Early Europeans unable to stomach milk
6. European launch of International Polar Year 2007-2008
7. IDIBAPS participates in European Network on antibiotic resistances and hospital infections
8. European launch of International Polar Year 2007-2008
9. European Federation of Biotechnology and Elsevier announce launch of biotechnology journal
10. Putting a face on the earliest modern Europeans
11. European Union outpaces United States on chemical safety

Post Your Comments:

(Date:7/22/2020)... , ... July 21, 2020 , ... ... transformation and innovation in technology and compliance, announces a new solution to manage ... must ensure every layer of their technology stack complies with FDA and global ...
(Date:7/18/2020)... ... ... Commercial launch readiness is a critical stage in a product life cycle. While ... global economic downturn will only increase price pressures overall for the industry. The era ... from every product launch is critical. However, history shows that only a third of ...
(Date:7/10/2020)... ... July 09, 2020 , ... Today CJ BIO announced the first in ... on the “fifth taste” phenomenon that is revolutionizing ingredient mixes, nutritional content and flavor ... live on Monday, July 13, 2020 at11:00 AM (CDT) during SHIFT20, the virtual edition ...
Breaking Biology News(10 mins):
(Date:8/12/2020)... BINGHAM FARMS, Mich. (PRWEB) , ... August 12, ... ... International Consulting Group, Inc. (EMMA International), a global leader in FDA compliance ... ranking of the nation’s fastest-growing private companies. The list represents a unique look ...
(Date:7/31/2020)... ... July 29, 2020 , ... R3 Stem Cell International is now offering patients ... million stem cells total, patients may choose which extremities they would like treated. , ... (BMC Musculoskelet Disord. 2016). At R3 International, umbilical cord tissue is obtained from a ...
(Date:7/31/2020)... ... July 29, 2020 , ... ... leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, ... have entered into a strategic partnership whereby Catalent will provide support for the ...
(Date:7/22/2020)... ... July 22, 2020 , ... Join experts from ... Sr. Manager Regulatory Solutions, in a one hour live webinar on Thursday, ... body in China for drugs and medical devices. Specifically, for medical devices, the NMPA ...
Breaking Biology Technology:
Cached News: